RIPK3 exhibits reduced expression levels in the majority of cancers, with the exception of Glioblastoma (GBM), Ovarian Cancer (OV), pancreatic adenocarcinoma (PAAD), and cholangiocarcinoma (CHOL), where it demonstrates elevated expression levels compared to their respective normal tissues (Figure 3C). Here, RIPK3 is linked to ovarian carcinoma.